RxDoctor Payments Data

Jacob Abraham, DO

Family Medicine · Douglas, GANPI 1528588142

Payments from drug & device makers

$4,040in general payments, 2019–2025

Across 103 payments — averaging $39.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Amgen$449
  • Johnson & Johnson$330
  • GSK$314
  • Novo Nordisk$302
  • AstraZeneca$282
  • plus $1K from 20 others

What the payments were for

  • Consulting fees$1,25031%
  • Food & beverage$2,79069%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,040 in reported general payments places this provider in the 80th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$33,822
Medicare patients
78
Services billed
681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide93$125,227
EliquisApixaban98$94,005
MounjaroTirzepatide59$64,502
FarxigaDapagliflozin Propanediol49$60,743
LinzessLinaclotide59$42,282
JanuviaSitagliptin Phosphate34$27,187
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$26,633
TrulicityDulaglutide19$24,887
FycompaPerampanel19$23,540
JardianceEmpagliflozin24$19,464
UbrelvyUbrogepant11$13,728
Ondansetron Hcl79$10,995
Combivent RespimatIpratropium/Albuterol Sulfate21$10,370
EntrestoSacubitril/Valsartan11$10,292
SymbicortBudesonide/Formoterol Fumarate35$9,300

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$302$125,22793 claims
PfizerEliquis$25$94,00598 claims
Lilly USA, LLCMounjaro, Trulicity$188$89,38878 claims
AstraZenecaFarxiga, Symbicort$282$70,04284 claims
AbbVieLinzess, Ubrelvy$183$56,01070 claims
GSKTrelegy Ellipta, Breo Ellipta$314$35,46848 claims
Boehringer IngelheimJardiance, Combivent Respimat$39$29,83445 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Douglas

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →